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Besides positive and negative symptoms, the schizophrenia
syndrome is characterized by various deﬁcits in cognitive
domains. This progressive neurocognitive impairment
deeply impacts the lives of those afﬂicted and their families
and is responsible for worsening of social abilities. In a
large-scale naturalistic open-label study of ﬁrst-episode
schizophrenia patients, Segarra et al. [1] have proven that
men have an earlier age of onset, poorer premorbid func-
tioning and a higher presence of prodromal and negative
symptoms compared with women. Women again show a
better social outcome with more stabile relationships.
Especially among women, acute stress precedes the onset of
psychosis. However, at the 2-year follow-up under risperi-
done treatment, in both genders, the outcome improved
signiﬁcantly, which was more pronounced in men. How-
ever, in this study, non-deﬁcit and chronic schizophrenia
patients have been investigated. Re ´thelyi et al. [2] investi-
gated cognitive functioning including working memory,
attention, short-term memory, verbal memory and cognitive
ﬂexibility in these both groups and found that patients with
deﬁcit schizophrenia suffer from more severe neurocogni-
tive impairment with cognitive ﬂexibility being an inde-
pendent predictor of outcome. The genetic background may
inﬂuence cognitive deﬁcits in these patients. Accordingly,
Lennertz et al. [3] show the T allele of a promoter variant of
the SHANK1 gene leading to impairments in working
memory in schizophrenia patients and subjects at risk for
psychosis. This is an interesting ﬁnding considering that
SHANK1 knockout mice entail altered memory functions
along with reduced dendritic spines and postsynaptic den-
sity, which also are features of schizophrenia. Cognitive test
performance also serves as separator between schizophrenia
and bipolar disorder. In this context, inhibitory control,
which includes aspects of cognitive and behavioral control
in processes of maintaining contextual information, may
discriminate schizophrenia from affective disorders.
Christodoulou et al. [4] detected more pronounced deﬁcits
of inhibitory control in schizophrenia patients with familial
risk compared to patients with bipolar disorder.
One less familiar feature of schizophrenia is the occur-
rence of motor deﬁcits. Spontaneous parkinsonism
including bradykinesia, rigidity and tremor was investi-
gated by Peralta et al. [5] in 200 drug-naı ¨ve ﬁrst-episode
schizophrenia patients. The most frequent sign was rigid-
ity, followed by bradykinesia, which was related to nega-
tive symptoms. Rigidity was related to neurological soft
signs and tremor to dyskinetic movements. The authors
found the NINDS criteria for spontaneous parkinsonism
being the most suitable instrument to assess these symp-
toms. Second-generation antipsychotics induce less motor
symptoms, but extrapyramidal adverse events and other
side effects such as weight gain and prolactin-related
symptoms have been found to be more frequently present
in patients treated with risperidone long-lasting injectable
(RLAI) compared to aripiprazole treatment by de Arce
Cordo ´n et al. [6]. However, relapse occurred in 27% of the
patients treated with aripiprazole and only 16% of the
RLAI-treated patients. Riedel et al. [7] highlight ethical
and medico-legal aspects of clinical trials of new drugs
with special focus on placebo-controlled trials and with-
drawal conditions in schizophrenia patients. The Trial
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sus criteria that are important to ensure the patient’s safety.
These criteria should be evaluated using standardized rat-
ing scales applying established cutoff criteria. Another
aspect of burden of disease is covered by the study of
Mo ¨ller-Leimku ¨hler and Wiesheu [8]. They investigated
caregivers, mainly mothers of adult children suffering from
schizophrenia, and found expressed emotions and per-
ceived social support predictive for caregiver’s burden,
whereas, with regard to the patient’s variables, regular
employment reduced caregiver’s distress. The authors
conclude that family interventions should improve dys-
functional interactions and enhance the carers’ social
activities.
Despite enormous efforts in neuroscience research, the
pathophysiology of schizophrenia is not well understood.
Varadarajulu et al. [9] investigated expression of the his-
tidine triad nucleotide-binding protein-1 (HINT1) in the
dorsolateral prefrontal cortex and thalamus of schizophre-
nia patients. HINT1 was downregulated in the prefrontal
cortex and upregulated in the thalamus. Since this protein
is important in control of transcriptional processes, cellular
stress and apoptosis, it may represent a potential target for
future treatment studies in animal models. In the patho-
physiology of schizophrenia, an inﬂammatory process
since some decades stays in focus. Aslan et al. [10] start an
alternative approach by investigating IgG antibodies to the
West Nile virus in 112 schizophrenia patients and 162
controls in Turkey. These antibodies were detected in 6
schizophrenia patients and 5 controls, suggesting no rela-
tionship between this virus and schizophrenia symptoms.
Albeit, further prospective studies investigating the rela-
tionship between environmental factors like virus diseases
and obstetric complications during neurodevelopment and
onset of disease during young adulthood are needed to
elucidate pathophysiological aspects of psychosis.
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